The above results potentially indicated that HNRNPH1 was an important molecular marker for CML progression and may help improve treatment, such as early turn to more efficacious TKIs or combination chemotherapy. Here, HNRNPH1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.